According to filings with the U.S. Securities and Exchange Commission, Key Proteo is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Executive, Sihoun Hahn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Key Proteo
Current newborn screenings cannot detect many treatable genetic diseases, which can become fatal without effective and early treatment. Key Proteos ultimate goal is to dramatically improve and expand the current Newborn Screening programs and subsequently provide early intervention of genetic diseases before they are clinically manifested. Key Proteo is specialized in multiplex analysis for any extremely low abundance proteins from a few drops of blood (DBS) using surrogate peptide markers by mass spectrometry. With this new technology, we target new or existing genetic conditions to change their clinical course and ensure better quality of life for our patients.

To learn more about Key Proteo, visit http://www.keyproteo.com/

Contact:
Sihoun Hahn, Executive
206-339-7515

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.